The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A combined blockade of V-domain Ig suppressor of T-cell activation (VISTA) and PD-1 is a promising new cancer treatment option, which was efficient in murine tumor models and is currently tested in first phase I studies. Here, we analyzed the VISTA expression in a large and well-characterized gastric cancer (GC) cohort on 464 therapy-naive GC samples and 14 corresponding liver metastases using immunohistochemistry. Staining results were correlated with clinico-pathological characteristics, genetic alterations and survival. VISTA expression in tumor cells was detected in 41 GCs (8.8%) and 2 corresponding liver metastases (14.3%). Moreover, VISTA expression in immune cells was observed in 388 GCs (83.6%) and 6 liver metastases (42.9%). VISTA expression was associated with the Laurén phenotype, tumor localization, Epstein–Barr virus infection, KRAS- and PIK3CA-mutational status and PD-L1 expression. There was no significant correlation with patient outcome. Moreover, a change of VISTA expression in immune cells during tumor progression was observed. The co-incidence of VISTA and PD-L1 expression indicates a dual immune evasion mechanism of GC tumor cells and makes GC an interesting target for novel combined immune checkpoint inhibitor treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×
“Nevertheless, all kind of tumors, including microsatellite stable and EBV-negative GCs, need strategies to evade immune attacks.(6) This leads to the conjecture that malignant tumors apply additional or supplementary immune escape mechanisms.”
BackgroundWang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · cited 1×
“Moreover, MSI GCs are characterized by a highmutational load, which is associated with a better response to anti-PD-1/PD-L1 immune checkpoint therapies in several tumor entities.(5) Nevertheless, all kind of tumors, including microsatellite stable and EBV-negative GCs, need strategies to evade immune attacks.”
BackgroundImmune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236 · cited 4×
“Whole tissue sections from GCs and corresponding liver metastases were stained with an antibody directed against VISTA.”
BackgroundInfluential
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 314
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Huang, X., Zhang, X., Li, E., Zhang, G., Wang, X., Tang, T., Bai, X., & Liang, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00917-y · Cited by 231
“showed that the number of VISTA-positive immune cells increased significantly from tumor category pT1 to pT2 and decreased significantly from pT2 to pT3 in gastric cancer (GCs) [45].”
Background
Metadata
- Authors
- Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-02-21
- Volume
- 6
- Issue
- 4
- Pages
- e1293215
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2590903145
- Cited by
- 156
- References
- 7
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? https://app.cochat.ai/papers/10.1080/2162402x.2017.1293215
- The paper
- Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C. (2017). The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? OncoImmunology. https://doi.org/10.1080/2162402x.2017.1293215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.